Oral anticancer drug Nexavar granted KFDA approval

Published: 2006-07-03 06:58:00

Updated: 2006-07-03 06:58:00

Bayer Korea announced on June 28 that the Korea Food and Drug Administration (KFDA) has approved the local marketing of Nexavar (sorafenib) tablets for the first-line treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer.

Nexavar is co-developed by Bayer HealthCare A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK